FRENCH INNOVATIVE LEUKEMIA ORGANISATION
French Innovative Leukemia Organization - FILO
FILO is a nonprofit, institutional group of clinical research in Chronic Lymphocytic Leukemia (LLC) Waldenstrom disease (MW)
FILO : Chronic Lymphoid Leukemia (CLL) and Waldenström's ...
of research in the field of Chronic Lymphoid Leukemia (CLL) Acute Myeloblastic Leukemia (AML) ... Alfa Leukemia French Association; American Society oh Hematology ...
French Innovative Leukemia Organization (FILO)
French Innovative Leukemia Organization (FILO) · Develop clinical and translational research · Promote prospective multi-centre clinical trials with an academic ...
French Innovative Leukemia Organization (FILO), France - Nature
Each position links to the corresponding table where French Innovative Leukemia Organization (FILO) is listed. Position by research output Share. Global, France ...
... French Innovative Leukemia Organization. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk ...
FRENCH INNOVATIVE LEUKEMIA ORGANISATION (GROUPE FILO)
FRENCH INNOVATIVE LEUKEMIA ORGANISATION (GROUPE FILO). institutions.detail.person.activities. Public funding body; Sponsor of clinical trial.
... French Innovative Leukemia Organization (FILO) group. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Entities - Institut Carnot OPALE
The ALFA group (Acute Leukemia French Association) is a multidisciplinary association ... The FILO Group "French Innovative Leukemia Organization" encompassed a ...
French Innovative Leukemia Organization (FILO) | Institution outputs
The articles listed below published by authors from French Innovative Leukemia Organization (FILO), organized by journal and article, represent the research ...
Recommendations of the French CLL Study Group (FILO) - PubMed
The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here a …
(FILO) Study. of CLL patients after FCR. A French Innovative ...
of CLL patients after FCR. A French Innovative Leukemia Organization. Increased rituximab exposure does not improve response and outcome. Version 3. HAEMATOL ...
FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (F.I.L.O.).
FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (F.I.L.O.). Civic and Social Organizations. Tours, Centreval De Loire 31 followers.
FILO French Innovative Leukemia Organization Trials - Larvol Sigma
Trial + Data / Events, Status, Ph, N, Region, Interventions, Sponsor, Conditions, Primary compl, Study compl. KILADJIAN, Jean Jacques ...
French Observational Study of Patients with Chronic Lymphocytic ...
... Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings (FOLLOW). F. French Innovative Leukemia Organisation. Status. Enrolling. Conditions.
Increased rituximab exposure does not improve response ... - PubMed
... lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Chronic Lymphocytic Leukemia trials in Paris, Île-de-France
French Innovative Leukemia Organisation. Paris, France and 33 other locations. Clinical trials. Find clinical trialsTrials by location. Research sites. Find ...
French foundation for cancer research - Donate Cancer research ...
The French foundation for cancer research Institut Curie fight against cancer thanks to an hospital, with the best experts, an internationally-renowned ...
Recommendations for the Management of Patients with Hairy-Cell ...
... Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group. by. Jérôme Paillassa. Jérôme Paillassa.
Paper: Lenalidomide Consolidation Improves Measurable Residual ...
... Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Program: Oral and Poster Abstracts Session: 642 ...
5.5-year results from the phase 2 ICLL-07 FILO trial | Blood Advances
the French Innovative Leukemia Organization (FILO) CLL group. Crossmark: Check for Updates. Blood Adv (2023) 7 (15): 3936–3945. https://doi ...